Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Receivables: 2019-2024

Historic Receivables for Eton Pharmaceuticals (ETON) over the last 6 years, with Dec 2024 value amounting to $5.4 million.

  • Eton Pharmaceuticals' Receivables rose 133.98% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year increase of 105.48%. This contributed to the annual value of $5.4 million for FY2024, which is 57.17% up from last year.
  • Eton Pharmaceuticals' Receivables amounted to $5.4 million in FY2024, which was up 57.17% from $3.4 million recorded in FY2023.
  • Eton Pharmaceuticals' 5-year Receivables high stood at $5.4 million for FY2024, and its period low was $48,000 during FY2020.
  • Moreover, its 3-year median value for Receivables was $3.4 million (2023), whereas its average is $3.5 million.
  • Per our database at Business Quant, Eton Pharmaceuticals' Receivables plummeted by 89.85% in 2020 and then skyrocketed by 10,316.67% in 2021.
  • Over the past 5 years, Eton Pharmaceuticals' Receivables (Yearly) stood at $48,000 in 2020, then surged by 10,316.67% to $5.0 million in 2021, then plummeted by 62.96% to $1.9 million in 2022, then spiked by 84.18% to $3.4 million in 2023, then surged by 57.17% to $5.4 million in 2024.